Loading organizations...
resTORbio operates as a clinical-stage biopharmaceutical company, dedicated to developing novel therapeutics for conditions associated with aging. The company’s primary focus lies in targeting fundamental biological pathways, notably by advancing selective TORC1 inhibitors. This approach aims to address a range of diseases, including certain respiratory and neurological disorders, by intervening in the cellular mechanisms underlying the aging process.
The company was incorporated in July 2016, co-founded by David Steinberg and Chen Schor. Their combined expertise in biopharmaceutical development and strategic leadership drove the establishment of resTORbio. The founding insight stemmed from the recognition of specific biological pathways’ pivotal role in aging and the potential to create targeted pharmaceutical interventions to treat age-related pathologies.
resTORbio intends for its products to serve patients afflicted with various chronic conditions that manifest or worsen with age. The company’s overarching vision is to pioneer innovative treatment options that not only manage symptoms but also modify disease progression, thereby significantly enhancing the health and overall quality of life for an expanding global aging population.
resTORbio has raised $40.0M across 1 funding round.
resTORbio has raised $40.0M in total across 1 funding round.
resTORbio is a clinical-stage biopharmaceutical company developing novel therapeutics targeting the biology of aging, particularly immunosenescence—the age-related decline in immune function that increases susceptibility to diseases like respiratory tract infections (RTIs) in the elderly.[1][2] Its lead product candidate, RTB101, is an oral, selective TORC1 inhibitor designed to restore immune function, with clinical trials demonstrating potential in reducing RTIs and exploring applications in Parkinson's disease (PD) by inducing autophagy to clear toxic protein aggregates.[1][2][5] The company serves elderly patients and those with aging-related conditions, addressing unmet needs in diseases without approved therapies, though growth momentum appears limited by its clinical-stage status and focus on high-risk biotech development as of 2020 updates.[1][2]
resTORbio, based in Massachusetts, emerged from research on the mTOR pathway, an evolutionarily conserved mechanism regulating aging and organ function decline.[1][2] Co-founded by Dr. Joan Mannick, who serves as Chief Medical Officer, the company built on preclinical evidence that TORC1 inhibition extends lifespan and improves healthspan in aging models.[2] Key early traction came from clinical trials of RTB101, including a randomized, placebo-controlled study showing immune restoration potential, with a pivotal 2020 announcement of interim Phase 1b/2a results in PD patients confirming blood-brain barrier penetration and tolerability.[2][5] This positioned resTORbio (NASDAQ: TORC) as a leader in aging-focused immunotherapy, though no recent founding year is specified in available data.[1]
resTORbio rides the aging biology revolution in biotech, targeting immunosenescence and mTOR pathways amid rising elderly populations and demand for longevity therapeutics.[1][2] Timing aligns with advances in autophagy induction for neurodegeneration—key in PD, Alzheimer's, and Huntington's—fueled by market forces like unmet needs in aging diseases and investor interest in healthspan extension.[2] It influences the ecosystem by validating TORC1 inhibition clinically, potentially enabling combo therapies and inspiring competitors in geroscience, though biotech risks like trial outcomes temper broader impact.[1][5]
resTORbio's path hinges on advancing RTB101 through later-stage trials for RTIs or PD, with next steps likely including full Phase 2 data readouts and expansion to combo regimens or new indications like other protein-aggregate diseases.[2] Trends in geroscience and autophagy modulators will shape its trajectory, bolstered by aging demographics, but success depends on regulatory milestones absent recent updates. Its influence could grow by pioneering immune restoration in aging, circling back to its core mission of combating immunosenescence to redefine elderly care.[1][2]
resTORbio has raised $40.0M in total across 1 funding round.
resTORbio's investors include OrbiMed, Fidelity Management & Research Company, Nest.Bio Ventures, Quan Capital, Rock Springs Capital.
resTORbio has raised $40.0M across 1 funding round. Most recently, it raised $40.0M Series A in November 2017.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Nov 1, 2017 | $40.0M Series A | OrbiMed | Fidelity Management & Research Company, Nest.Bio Ventures, Quan Capital, Rock Springs Capital |